Max Håkan Mitteregger

Fjärde AP-fonden (AP4) is the pension fund management subsidiary of the Government of Sweden. Also known as Fourth AP Fund, the firm was founded in 1974 and is headquartered in Stockholm. AP4 provides pension fund management services for employees of Swedish corporations. The firm manages The Fourth Swedish National Pension Fund, which is a buffer fund for the earnings-related part of the state pension scheme. They are a socially responsible investor and signatory to the UN Principles for Responsible Investment which integrates ESG criteria in their investment processes.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark.

Aqilion AB is a venture capital firm. The firm was founded in 2002 by Jan Ekberg and Mats G. Ringesten. It's headquartered in Helsingborg, Sweden.

Respiratorius AB engages in the development of drug candidates for Chronic Obstructive Pulmonary Disease, asthma, and cancer. The company was founded by Lars Christer Fedrik Fåhraeus and Staffan Skogwall in 1999 and is headquartered in Lund, Sweden.

CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden.

Part of Roche Holding AG, Roche AB is a biotechnology company founded in 1896. The company is based in Solna, Sweden and creates innovative treatments to help millions of patients worldwide. Roche actively seeks partnerships with healthcare providers, academia, patient associations, organizations, external companies, and startups to identify needs that form the basis for collaborations. Roche is one of the world's largest research-based biotechnology companies, focusing on advancing science to improve people's lives. The Swedish company develops both drugs and diagnostics and has great respect for the multiple perspectives required to create tomorrow's healthcare.

Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden.

Skane University Hospital operates a search service called Hitta Vård, which provides contact information for public and private healthcare providers in the Skåne region of Sweden. The private company is based in Malmö, Sweden. The service is financed by Region Skåne.

Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway.

Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden.

Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019.

Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden.

KarSar Fastigheter AB provides security brokerage and real estate services. The private company is based in Stockholm, Sweden and has subsidiaries in Sweden.

Samtrans Skol- och Handikapptransporter Stockholm AB specializes in carrying out, administering, and coordinating travel for people with special needs. It offers safe travel such as wheelchair taxi and travel service, as well as school chairs and special travel for people with special needs. The firm provides its services to schools, workplaces, day care centers, and healthcare providers. The company is headquartered in Solna, Sweden.

Pelago Bioscience AB is a specialized CRO that focuses on their patented cetsa® technology. The private company is based in Solna, Sweden. The technology can be applied throughout all steps of the drug discovery value chain. Pelago Bioscience provides bespoke projects in a wide range of services. The Swedish company's cetsa® navigate enables rapid target engagement confirmation, cetsa® navigate ht is for efficient high-throughput discovery, and cetsa® explore is a mass spectrometry-based approach allowing unbiased proteome-wide investigation. The Pelago Knowledge Center is a collection of resources used to drive innovation in drug discovery focusing on excellence in target engagement.

Neogap Therapeutics AB is a Swedish clinical stage biopharmaceutical company. The private company is based in Stockholm, Sweden.